Beagle Varieties

Two Varieties, One Breed

The American Kennel Club recognizes 2 varieties of beagle, distinguished solely by height:

• 13-inch variety — not exceeding 13 inches (33 cm) at the shoulder.
• 15-inch variety — over 13 inches but not exceeding 15 inches (38 cm) at the shoulder.

Both varieties share the same breed standard in all other respects: tricolor or bicolor coat, broad skull, square muzzle, pendant ears, and sturdy, compact build. In the show ring, the 2 varieties compete separately but are otherwise genetically and phenotypically similar.

This distinction matters for research because it establishes that "beagle" is not a single uniform type. Even within AKC-registered lines, substantial variation exists in size, build, and underlying genetics.

The Research Beagle

Laboratory beagles are not show dogs. They are bred from closed colonies maintained by companies like Marshall BioResources over decades of selective breeding for traits that serve the laboratory, not the breed ring.

• Size range — research beagles typically weigh 8-14 kg (17-31 lbs) at study age. This is the smaller end of the breed's natural range, favoring the 13-inch variety.
• Why smaller — smaller dogs require less test substance per dose (drugs are dosed per kilogram of body weight), occupy less cage space, are easier to restrain for procedures like oral gavage, and cost less to house and feed.
• Physical differences — colony beagles often differ from show lines in subtle ways: narrower skulls, less muscular build, lighter bone structure. These differences reflect decades of selection for different criteria.

Colony vs Show Standards

The divergence between colony beagles and show beagles is real but undocumented in any formal standard. Colony breeders select for:

• Docility — willingness to accept handling, restraint, and invasive procedures.
• Health — absence of common breed problems (hip dysplasia, epilepsy, hypothyroidism) that would complicate study interpretation.
• Uniformity — consistent body size, growth rate, and organ weights to minimize inter-animal variability in study data.
• Fecundity — reliable fertility, adequate litter sizes, and good maternal behavior.

Show breeders select for:

• Conformation — adherence to the physical breed standard.
• Movement — correct gait and structure.
• Temperament — alertness and "merry" disposition per breed standard.

After decades of selection for completely different traits within closed populations, colony beagles and show beagles are genetically distinguishable. They remain the same breed, but they are functionally different populations.

The Celecoxib Problem

The most scientifically significant consequence of colony-specific genetics involves drug metabolism. The case of celecoxib — a COX-2 inhibitor (brand name Celebrex) — illustrates the issue precisely.

• Bimodal pharmacokinetics — in certain beagle colonies, celecoxib produces a bimodal distribution of plasma drug levels. Some dogs metabolize the drug rapidly (low plasma levels), while others metabolize it slowly (high plasma levels). There is no middle ground.
• Colony-specific polymorphisms — the bimodal pattern is caused by genetic polymorphisms in cytochrome P450 enzymes (specifically CYP2D15) that are prevalent in some colonies but not others. These polymorphisms are artifacts of the closed colony's genetic structure.
• Implications for study validity — if a toxicology study is conducted in a colony with a high frequency of poor metabolizers, the dogs will show exaggerated drug exposure and potentially exaggerated toxicity. If the same study is conducted in a colony with predominantly rapid metabolizers, the drug may appear safer than it actually is.

This is not a theoretical concern. It means that the safety profile of a drug can vary depending on which beagle colony was used to test it. Two pharmaceutical companies testing the same compound in beagles from different colonies could reach different conclusions about its toxicity.

What This Means for Translation

The laboratory beagle is supposed to serve as a model for predicting human responses. But colony beagles are not representative of dogs broadly, let alone humans:

• Genetic bottleneck — colony beagles have reduced genetic diversity compared to the breed at large, and dramatically reduced diversity compared to mixed-breed dogs or humans.
• Colony-specific traits — metabolic polymorphisms, immune system profiles (DLA restriction), and physiological baselines vary between colonies.
• Environmental uniformity — colony beagles live in controlled environments from birth that bear no resemblance to the conditions of human patients who will ultimately take the tested drugs.

The "standardized" beagle is standardized within a colony. Between colonies, and certainly between colony beagles and the human patients they are meant to represent, the standardization breaks down.

Sources

1. 1.AKC Breed Standard, 2024. American Kennel Club official standard for the Beagle, including the 13-inch and 15-inch variety designations.
2. 2.Colony Pharmacogenomics Studies, 2018. Research documenting CYP2D15 polymorphisms in laboratory beagle colonies and the resulting bimodal pharmacokinetics of celecoxib and other substrates.
3. 3.Comparative Breed Analysis, 2020. Genetic comparison of laboratory beagle colonies with show-line and pet beagle populations, including DLA diversity and population structure analysis.